Goichot-Bonnat L, De Beauregard C, Saragoussi J J, Pouliquen Y
J Fr Ophtalmol. 1987;10(3):207-11.
Topical cyclosporine A (2%) has been used to prevent corneal graft rejection in high risk patients. The treatment was begun 48 h at least before surgery. 3 patients (4 eyes) suffering from metaherpetic keratitis were placed under this treatment for a long time due to the delay to obtain a corneal donor. Their observation while treated showed a remarkable slow-down of the inflammation both in conjunctivae and corneas. This confirms if necessary the role of T lymphocytes in metaherpetic corneal diseases and the clinical modulation effect of cyclosporine A on these T cells.
局部用环孢素A（2%）已用于预防高危患者的角膜移植排斥反应。该治疗至少在手术前48小时开始。3例（4眼）患有复发性疱疹性角膜炎的患者因延迟获得角膜供体而长期接受该治疗。在治疗期间对他们的观察显示，结膜和角膜的炎症均显著减缓。这在必要时证实了T淋巴细胞在复发性疱疹性角膜疾病中的作用以及环孢素A对这些T细胞的临床调节作用。
